Department of Thoracic Surgery, General Hospital of Chengdu Command, Chengdu, China.
J Surg Res. 2013 Dec;185(2):784-9. doi: 10.1016/j.jss.2013.07.012. Epub 2013 Jul 31.
Chylothorax is a pathologic condition defined by an accumulation of lymphatic fluid, the chyle, in the thorax. Postoperative chylothorax is a potentially lethal complication, with a reported mortality rate of 15.4%-25%.
Esophageal cancer patients hospitalized for elective radical esophagectomy by thoracotomy (n = 10,574) were consecutively enrolled between January 1996 and December 2011. Patients (n = 306) who experienced post-esophagectomy chylothorax were assigned to a 48-h (group A, n = 186) or to a 2-wk (group B, n = 120) conservative treatment regimen. For patients with a daily chylothorax output >1000 mL, thoracic duct ligation (TDL) was performed by thoracotomy. Measured outcomes included frequency of TDL, overall and treatment-specific morbidity and mortality rates, and the rate of chylothorax recurrence.
A total of 171 patients (171 of 306 [55.9%]) underwent TDL. A larger proportion of patients in group A required TDL compared with group B (72.6% versus 30.0%, P < 0.001). Group A had a significantly higher rate of overall morbidity compared with group B (31.7% versus 19.2%, P = 0.02). Moreover, the overall mortality rate was significantly higher in group A (14.0% versus 4.2%, P = 0.006). Chylothorax recurred in nine patients (9 of 306 [2.9%]), and there was no difference between the two groups (3.2% versus 2.5%, P = 1.000).
The 2-wk regimen reduced the requirement for TDL and the overall morbidity and mortality rates compared with the 48-h regimen. Importantly, this regimen does not increase the risk of chylothorax recurrence.
乳糜胸是一种以胸腔内淋巴液积聚为特征的病理状态。术后乳糜胸是一种潜在的致命并发症,据报道死亡率为 15.4%-25%。
1996 年 1 月至 2011 年 12 月,连续纳入 10574 例因择期根治性经胸食管癌切除术住院的食管癌患者。将术后发生乳糜胸的 306 例患者分为 48 小时(A 组,n = 186)或 2 周(B 组,n = 120)保守治疗组。对于每日乳糜胸引流量>1000 毫升的患者,行开胸胸导管结扎术(TDL)。观察指标包括 TDL 发生率、总并发症发生率和病死率、治疗特异性并发症发生率和病死率以及乳糜胸复发率。
共有 171 例(306 例中的 171 例[55.9%])患者接受 TDL。与 B 组相比,A 组患者 TDL 比例更大(72.6%比 30.0%,P < 0.001)。A 组总并发症发生率显著高于 B 组(31.7%比 19.2%,P = 0.02)。此外,A 组总病死率显著高于 B 组(14.0%比 4.2%,P = 0.006)。9 例(306 例中的 9 例[2.9%])患者乳糜胸复发,两组间差异无统计学意义(3.2%比 2.5%,P = 1.000)。
与 48 小时方案相比,2 周方案可降低 TDL 需求及总并发症发生率和病死率。重要的是,该方案并不增加乳糜胸复发的风险。